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Abstract
Background: Observational research suggests that combined therapy with Vitamin C, thiamine and hydrocortisone
may reduce mortality in patients with septic shock.
Methods and design: The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) trial is a multicenter, double-blind,
adaptive sample size, randomized, placebo-controlled trial designed to test the efficacy of combination therapy
with vitamin C (1.5 g), thiamine (100 mg), and hydrocortisone (50 mg) given every 6 h for up to 16 doses in patients
with respiratory or circulatory dysfunction (or both) resulting from sepsis. The primary outcome is ventilator- and
vasopressor-free days with mortality as the key secondary outcome. Recruitment began in August 2018 and is
ongoing; 501 participants have been enrolled to date, with a planned maximum sample size of 2000. The Data and
Safety Monitoring Board reviewed interim results at N = 200, 300, 400 and 500, and has recommended continuing
recruitment. The next interim analysis will occur when N = 1000.
This update presents the statistical analysis plan. Specifically, we provide definitions for key treatment and outcome
variables, and for intent-to-treat, per-protocol, and safety analysis datasets. We describe the planned descriptive
analyses, the main analysis of the primary end point, our approach to secondary and exploratory analyses, and
handling of missing data. Our goal is to provide enough detail that our approach could be replicated by an
independent study group, thereby enhancing the transparency of the study.
Trial registration: ClinicalTrials.gov, NCT03509350. Registered on 26 April 2018.
Keywords: Statistical analysis plan, Adaptive sample size, Vitamin C, Thiamine, Steroids, Sepsis, Septic shock
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Introduction
Sepsis is a devastating condition for which there are few
effective therapies. With the exception of antimicrobials
and vasopressors, pharmaceutical interventions have
failed to improve patient outcomes in clinical trials [1,
2]. As a result, contemporary treatment remains limited
to early appropriate antibiotics, fluid resuscitation,
hemodynamic support, and control of infection [3]. Re-
cently, combination therapy with vitamin C, thiamine,
and steroids has garnered interest following an observa-
tional cohort study, with historical controls, that sug-
gested an absolute reduction in mortality of over 30%
[4]. The potential benefit of this treatment regimen is
biologically plausible [5]. We designed and implemented
a multicenter, double-blinded, randomized, placebo-
controlled, adaptive sample size clinical trial to investi-
gate the efficacy of this combination therapy in patients
with sepsis.
The protocol for the Vitamin C, Thiamine, and Ste-
roids in Sepsis (VICTAS) trial (NCT03509350) was
previously reported [6]. Briefly, initial enrollment was
planned to include up to 500 participants and con-
tinue to a maximum of 2000 participants if no stop-
page rules are triggered. Stoppage rules were defined
a priori and will determine the final number of par-
ticipants enrolled in the trial. Participants are aged
18 years or older with suspected or confirmed sepsis
who are either admitted to, or awaiting admission to,
an intensive care unit (ICU). The presence of sepsis
is evidenced by: 1) the ordering of blood cultures and
the administration of at least one antimicrobial agent;
and 2) acute respiratory and/or cardiovascular organ
dysfunction that is attributed to the sepsis event.
Randomization to either treatment or control must
occur within 24 h of onset of the first qualifying
organ dysfunction, and study drugs (or placebos)
must be started within 4 h of randomization. To date,
43 sites have been activated to enroll patients, and
501 patients have been enrolled.
Details of the statistical design and adaptations, includ-
ing sample size justification, interim analysis plans, and
the approach to multiplicity during interim looks were
published with the protocol. Interim analyses have oc-
curred at N = 200, N = 300, N = 400 and N = 500, and
the Data and Safety Monitoring Board has recom-
mended continuing recruitment at each time point.
Here, we describe in detail the statistical analysis plan
that will be used when the trial ends. This includes defi-
nitions of key treatment and outcome variables, defini-
tions of the analysis datasets, our approach to handling
missing data, our approach to analyzing primary, sec-
ondary, exploratory and safety end points, and the inclu-
sion of sensitivity analyses to explore the robustness of
our findings.
Treatment arms
Participants are randomized 1:1 to receive either inter-
vention or control, defined as follows.
Intervention
The intervention consists of intravenous vitamin C (1.5
g), thiamine hydrochloride (100 mg), and hydrocortisone
sodium succinate (50 mg) administered within 4 h of
randomization and then every 6 h thereafter. The inter-
vention continues until either the patient is discharged
from the ICU or 16 drug administrations have been
completed (96 h), whichever is first. On days when a pa-
tient is treated with open-label hydrocortisone at a dose
≥200 mg/day (or equivalent), study drug 3 (hydrocorti-
sone succinate) is withheld. If a subsequent daily medi-
cation check during the treatment period reveals that
open-label hydrocortisone has been decreased to <200
mg/day (or equivalent), study drug 3 (hydrocortisone
succinate) will be administered.
Control
The control condition involves matching placebos ad-
ministered intravenously within 4 h of randomization
and then every 6 h thereafter. Placebo administration
continues until either the patient is discharged from the
ICU or 16 drug administrations have been completed
(96 h), whichever is first. On days when a patient is
treated with open-label hydrocortisone at a dose ≥200
mg per day (or equivalent), study drug 3 (placebo) is
withheld. If a subsequent daily medication check during
the treatment period reveals that open-label hydrocorti-
sone has been decreased to <200 mg/day (or equivalent),
study drug 3 (placebo) will be administered.
End points
Primary end point
The primary end point for this trial is ventilator- and
vasopressor-free days (VVFD) on day 30 following mid-
night of the randomization day. This is computed as a
backwards count of consecutive whole days free of both
respiratory and vasopressor support between day 30 and
the most recent use of either respiratory or vasopressor
support (Fig. 1). Note that days free of respiratory and
vasopressor support that occur between periods with
support do not count towards VVFD. The day of
randomization is day 0 and the next calendar day is day
1. Day 0 will not contribute to the count because partici-
pants must require respiratory support or vasopressors
to be enrolled. For a day to count as free of both respira-
tory and vasopressor support, a patient cannot receive
any of the following on that calendar day: 1) mechanical
ventilation via an endotracheal tube or tracheostomy
tube; 2) noninvasive positive-pressure ventilation with
supplemental oxygen; 3) high-flow nasal cannula at ≥40
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l/min with a fraction of inspired oxygen ≥0.4; or 4) nor-
epinephrine, epinephrine, vasopressin, dopamine,
phenylephrine, angiotensin II, or other vasopressor
agents (not including pure inotropes) at any dose for any
duration.
Participants in need of respiratory or vasopressor sup-
port on day 30 will be assigned zero VVFDs. Participants
who die before day 30 will also be assigned zero VVFDs.
For participants alive but not observed to day 30 (e.g.,
participants who are discharged or transferred to an-
other facility), the last observed status will be carried for-
ward. Thus, if the participant was last seen on
respiratory or vasopressor support, it is assumed they
remained that way until day 30 and will thus be assigned
zero VVFDs. If the participant was last seen not requir-
ing respiratory or vasopressor support, it is assumed they
stayed that way until day 30 and the unobserved days
will count as VVFDs.
We note that it is possible a patient who is discharged
might experience a subsequent hospitalization during
which respiratory or vasopressor support is provided.
However, we are unlikely to have knowledge of such
events and they will not be counted against the VVFD
for the original enrollment; status at discharge for the
first hospitalization will be carried forward.
The count of VVFDs is an ordinal variable, with death
or the requirements for respiratory or vasopressor sup-
port resulting in lower scores, and sustained absence of
respiratory and vasopressor support resulting in higher
scores.
Key secondary end point
The secondary end point for this trial is 30-day mortal-
ity. The 30 days begins at midnight on the day of
randomization (day 0). A death within 30 days will count
towards this end point. Death is a binary variable. As
with VVFDs, we will use the last observed value carried
forward when a patient is discharged prior to day 30.
That is, a patient discharged alive will be assumed alive
at day 30.
Fig. 1 Illustration of the calculation of ventilator- and vasopressor-free days (VVFDs) under various scenarios
Lindsell et al. Trials          (2019) 20:670 Page 3 of 9
Additional exploratory end points
Additional exploratory end points are:
1. Change in the Sequential Organ Failure Assessment
(SOFA) score between baseline and day 4 [7].
2. A binary variable indicating mortality between the
time of randomization and 180 days following
midnight on the day of randomization.
3. A binary variable indicating mortality between the
time of randomization and departure from the ICU.
4. Length of ICU stay, measured in days, from
midnight following randomization to the day of
departure from the ICU; a partial day will count as
a whole day.
5. Length of hospital stay, measured in days, from
midnight following randomization to the day of
departure from the hospital; a partial day will count
as a whole day.
6. Renal replacement-free days at day 30, computed as
a backwards count of consecutive whole days free
of renal replacement therapy beginning at day 30
from midnight of the day of randomization (i.e., cal-
culation will follow the same rules as VVFD).
7. ICU delirium, measured as the number of whole
days alive and free of both delirium and coma
between midnight on the day of randomization and
day 5. Delirium and coma are assessed using the
confusion assessment method for the ICU (CAM-
ICU) [8, 9]. All coma- and delirium-free days count
towards this end point regardless of whether they
are consecutive or not. If multiple assessments are
done on a single day, all assessments must be free
of delirium and coma for the day to count towards
the end point.
8. Neurocognitive outcomes at 180 days measured
among survivors using the following instruments:
a) Attention (Wechsler Adult Intelligence Scale IV:
digit span) [10]
b) Delirium (telephone confusion assessment
method) [11]
c) Executive Functioning (Hayling test) [12]
d) Language (controlled oral word association test)
[13]
e) Orientation (telephone interview for cognitive
status) [14]
f) Memory (Wechsler Memory Scale IV:
paragraph recall) [15]
g) Reasoning (Wechsler Adult Intelligence Scale
IV: similarities) [15]
h) Activities of daily living (Katz) [16]
i) Employment (employment questionnaire)
j) Instrumental activities of daily living (functional
activities questionnaire) [17]
k) Depression (Beck Depression Inventory II) [18]
l) Post-traumatic stress disorder checklist for the
Diagnostic and Statistical Manual 5th revision
[19]
m) EuroQol, five dimensions [20]
Safety end points
Safety end points to be included in the safety analysis for
this trial include all potentially associated adverse events
(PAAEs). The prespecified PAAEs are:
 Nephrolithiasis
 Hemolysis
 Hypersensitivity reactions
 Injection site reactions
In addition, we will report other PAAEs that are not
listed above. All PAAEs will be characterized by the
nonstudy clinical care team managing the patient. Due
to the nature and clinical course of patients with sepsis
and septic shock, a substantial number of adverse events
are expected among participants, including but not lim-
ited to:
 Death
 Renal failure
 Respiratory failure
 Heart failure
 Pneumonia or other/new infection
 Deep vein thrombosis or pulmonary embolism
 Complications related to ICU procedures
 Arrhythmia
 Delirium
 Bowel ischemia
 Ileus
 Leukopenia or leukocytosis
 Anemia or thrombocytopenia
 Coagulopathy (disseminated intravascular
coagulation)
 Hypoglycemia
 Electrolyte abnormalities
These adverse events are common in sepsis and septic
shock and are thus not expected to reflect the safety of
the treatment regimen. Conversely, absence of these
events is expected to contribute to efficacy outcomes,
and several are included as efficacy end points. There is
no plan to summarize or report these events to
characterize safety.
Design considerations
The trial design, including adaptations, stopping rules
and power considerations, was previously described [6].
It is briefly reviewed here for context.
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Randomization
Participants are randomized in a 1:1 ratio to receive ei-
ther intervention or placebo. Randomization uses per-
muted small blocks of random size, stratified within site.
No other stratification or control for imbalance is being
used. The randomization schema is deployed via the
central investigational pharmacy.
Adaptations and stopping
The trial was designed to detect a moderate effect on
the primary end point of VVFDs, while allowing early
stoppage if a very large effect is observed on the second-
ary end point of mortality. Early interim analyses were
performed to compute the predicted probability of suc-
cess on the mortality end point with N = 200, 300, and
400 enrolled participants. Interim analyses include all
data, monitored and unmonitored, for completed partici-
pants, as well as information on the number of patients
enrolled who do not yet have outcomes available. Effi-
cacy stopping rules, but not futility stopping rules, were
in place for these early interim analyses. If a sufficiently
large effect was observed, accrual would have been
stopped, enrolled participants would have been followed
for outcomes and the primary analysis would have fo-
cused on the mortality end point.
Because the trial has proceeded beyond N = 400, add-
itional interim analyses will be conducted at N = 500,
1000, and 1500 based on both VVFDs and mortality.
Both futility and efficacy rules are defined for these in-
terims. Once a stopping rule has been triggered or when
2000 patients have been recruited, accrual will stop, all
enrolled participants will be followed for outcomes and
the primary analysis will focus on the VVFD end point.
Power and sample size
If the intervention truly causes a mortality difference of
20%, study power is approximately 99%, and the trial
would likely have stopped before 500 participants were
enrolled with a very high probability (>95%) of success.
For a true mortality difference of 5% and true average
improvement of 0.6 days free of respiratory or vasopres-
sor support for participants that do not die, the power of
the study is approximately 95%. The primary outcome
assessed if the study stops when N = 500, 1000, 1500, or
2000 participants is VVFDs. The overall type I error rate
for the trial is controlled at 2.5%. Thus, the early interim
analyses at N = 200, 300, and 400 were designed to con-
servatively spend alpha so that 2.4% remains for the ana-
lyses of 500 or more enrolled participants. Having
exceeded 500 participants, a more moderate effect on
mortality remains possible, and the trial is planned to
continue beyond 500 participants.
Definition of analysis sets
Intent-to-treat analysis set
All randomized participants will be included in the
intent-to-treat analysis set. The intent-to-treat partici-
pants will be used for all primary, secondary, and other
efficacy analyses. In these analyses, participants will be
classified according to the treatment to which they were
randomized, regardless of what treatments or how many
study treatments were given.
Participants who withdraw consent will be included in
the intent-to-treat analysis set. If, at the time consent
was withdrawn, the participant gave consent for observa-
tion of outcomes then observed outcomes will be used.
Otherwise, the last observed value will be carried
forward.
Per-protocol analysis set
All participants who are included in the intent-to-treat
analysis set who correctly receive at least four doses of
assigned study treatment (all three components of the
study drug or placebo, adjusted for open-label steroids)
and did not incur any major protocol deviations or viola-
tions will be included in the per-protocol analysis set. In
this analysis, participants will be classified according to
the treatment they received. Major protocol deviations
or violations will be identified prior to the unblinding of
the study for the final analysis and will include:
 Found to violate any inclusion or exclusion criterion
 Condition adjudicated not to be sepsis
 Received one or more doses of the unassigned study
treatment
 Study hydrocortisone (or placebo) not adjusted for
use of open-label steroids.
 Other protocol deviations classified as ‘major’ by a
majority vote of the Executive Committee, who shall
be blinded at the time of the vote
Safety analysis set
Participants who are randomized and receive at least
one administration of study treatment will be included
in the safety analysis set. If a subject received both pla-
cebo and active treatment, they will be considered as
having received active treatment. All other participants
will be classified as not having received active treatment.
Analysis
Timing of analysis
Once a decision to stop the trial has been made, the pri-
mary analysis may proceed after all enrolled participants
have completed the 30-day follow-up, 30-day data have
been monitored, and 30-day data are declared query
free. All data up to and including day 30 will be locked
at this time. Analysis of additional efficacy end points
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and long-term outcomes will proceed after all enrolled
participants have completed 180-day follow-up, the 180-
day data have been monitored, the 180-day data are de-
clared query free, and the remainder of the database has
been locked.
Blinding
Trial investigators and research teams are blinded to
treatment assignment. There are two groups of study
statisticians, one of which is performing the interim ana-
lyses and one of which is conducting the primary study
analyses. Neither group of statisticians is blinded. This
statistical analysis plan was drafted prior to the first in-
terim analysis and prior to unblinding.
Descriptive analysis
Using data pooled across all sites, the study sample will
be characterized based on demographic and clinical vari-
ables measured at randomization, unless otherwise indi-
cated. Specifically, the following variables will be
described:
1. Age (years)
2. Race (African American, Caucasian, other)
3. Ethnicity (Hispanic or Latino, not Hispanic or
Latino, or not reported)
4. Sex (male or female)
5. Education (less than high school, high school or
general education diploma, some college)
6. Body mass index (kg/m2)
7. Medical history (yes, no):
a) Diabetes
b) Cardiovascular disease
c) Neurological disease
d) Respiratory illness
e) Current cancer
8. Eligibility criterion (respiratory support, vasopressor
support, both)
9. Source of admission (emergency department,
intermediate care (or step-down unit), floor, other)
10. Admission reason (sepsis, other medical, urgent
surgical (necrotizing soft tissue, bowel obstruction,
bowel ischemia, burn, trauma), other surgical)
11. Baseline vital measurements (closest measurement
prior to time of randomization):
a) Heart rate (beats per minute)
b) Systolic blood pressure (mmHg)
c) Diastolic blood pressure (mmHg)
d) Mean arterial pressure (mmHg)
e) Respiration rate
f) Temperature (°C)
12. Baseline laboratory values (closest measurement
prior to time of randomization):
a) White blood cell count (K/mm3)
b) Platelets (K/mm3)
c) Hemoglobin (g/dL)
d) Lactate (mmol/L)
e) Creatinine (mg/dL)
13. Baseline severity:
a) Acute Physiology and Chronic Health
Evaluation II score (continuous score) [21]
b) SOFA score (continuous score)
c) CAM-ICU (delirium present or absent)
14. Infection, using final available value:
a) Infection source (lung, blood or vascular access,
urinary tract, intra-abdominal, skin or soft tis-
sue, central nervous system, bone or joint, other,
unknown; if no confirmed source available, use
final presumed source)
b) Gram-positive organism
c) Gram-negative organism
d) Fungal infection
e) Organism not identified
f) Other infection
g) Unknown infection
Categorical variables will be described using frequen-
cies and proportions. Continuous variables will be de-
scribed using mean and standard deviation, as well as
median and interquartile range (IQR). The sample will
be described overall and stratified by group assignment
according to the intent-to-treat principle. No statistical
testing will be done to compare characteristics between
groups.
Main analysis
The main analysis will be a simple comparison between
the two treatment groups according to the intent-to-
treat principle. If the study had stopped before N = 500,
the first analysis would have been based on mortality.
Because the study has proceeded to N = 500, the first
analysis will be based on VVFDs.
VVFDs
A Wilcoxon rank-sum test (i.e., Mann–Whitney U test)
will be used to compare VVFDs between treatment
groups using a one-sided alpha of 0.022. As described in
the adaptive design report, this threshold controls the
type 1 error accounting for multiple analyses at N = 500,
1000, 1500 and 2000 [6]. If the sample size had been
N < 500, the VVFD end point would have only been
tested if the mortality end point had been successful.
Mortality
Had the study stopped prior to N = 500, the mortality
end point would have been tested first with a chi-square
test using a one-sided alpha = 0.001 (i.e., 0.1%). Because
the study has reached N = 500, and is planned to
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continue enrollment, mortality will be compared be-
tween treatment groups only if there is a difference ob-
served on VVFDs. In this case, a one-sided alpha of
0.024 will be used.
We note that the Wilcoxon rank-sum test is equiva-
lent to a proportional odds model with one binary pre-
dictor, and the Chi-square test is equivalent to the test
of significance of a binary predictor in a logistic regres-
sion model. For simplicity in comparing the unadjusted
analyses to the adjusted analyses described later, we will
also report the odds ratios with 95% confidence
intervals.
Description of end points
End points will be described using median and IQR for
VVFDs and frequency and percentages for mortality.
The distribution of VVFDs will be described using histo-
grams. Mortality point estimates will be reported with
95% confidence intervals. Descriptions will be given
overall, and for each treatment group. Differences in me-
dian VVFDs will be computed with 95% confidence in-
tervals. Similarly, differences in proportions for mortality
will be calculated with 95% confidence intervals.
Sensitivity analysis
Our sensitivity analyses are not designed to preserve
type I error rates, but rather to explore possible sources
of bias that might inform interpretation of the main ana-
lysis. As such, all sensitivity analyses we will use a two-
sided alpha of 0.05. We will also emphasize the magni-
tude and confidence intervals of differences over statis-
tical significance.
Per-protocol analysis
We will duplicate our main analysis using the per-
protocol dataset.
Missingness
Due to the method of using last value carried forward to
assign unobserved outcomes, there will be no missing-
ness on the primary outcomes for the main analysis. We
will conduct one sensitivity analysis in which we will
replicate the main analysis but include only those partic-
ipants with observed outcomes.
Steroids
Since participants in either arm can receive open-label
steroids, we will replicate the primary analysis excluding
those who were treated with open-label steroids in the
placebo group.
Safety analysis
This study is not designed to test safety. No statistical
comparison of safety will be done. Safety end points will
be reported in tabular format, grouped by whether the
participant received any active treatment or not.
Adjusted analysis
We will use two approaches to estimate treatment ef-
fects adjusted for covariates. Generalized linear mixed
models will be used to estimate the conditional effect of
treatment with site as a random effect. Generalized esti-
mating equations will be used to estimate the marginal
effect of study treatment. Mortality will be modeled as-
suming a logit link function. A proportional odds model
will be specified for VVFDs. Models will consider base-
line variables as listed in the descriptive analysis. Mul-
tiple imputation based on predictive mean matching will
be used to overcome any missingness in covariates. Re-
stricted cubic splines will be used for addressing poten-
tial nonlinearities in the association between continuous
variables and outcomes. Some collinearity is expected
among baseline variables. If we observe substantial col-
linearity, such as a correlation greater than 0.6 or a vari-
ance inflation factor greater than 2.5, we will use a
principal components analysis approach where the first
principle component of the correlated variable group
will be included in the model. Interaction terms will not
be considered in the main adjusted analysis. Models will
be constructed based on the intent-to-treat principle. Ef-
fect sizes and overall fit will be emphasized for selecting
the final model; statistical significance alone will not be
used to decide which variables are included in the
models. Graphical approaches will be used to explore fit;
for example, residual plots can be used to identify issues
with the proportional odds assumptions and with non-
linearity. The Wald minus df can also be plotted to ex-
plore importance of individual predictors in the models.
The fitted models will then be applied to the per-
protocol analysis set in a sensitivity analysis. In addition,
if any multiple imputation were to be required, the fitted
models will be applied to complete cases.
Differential treatment effects and subgroup analysis
Using the fitted models from the principal adjusted ana-
lysis, we will evaluate the interaction between treatment
group assignment and each of the following variables:
sex, race, ethnicity, age, admission reason, source of ad-
mission, infection, baseline illness severity, baseline lactic
acid, and eligibility criteria. Interactions will not be
tested together within the same model, but will be tested
one by one. If any interaction achieves a P value ≤0.2,
we will report treatment effects within each subgroup
defined by that interaction variable.
Analysis of exploratory end points
A number of exploratory end points have been specified.
We will proceed with exploring the effect of treatment
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on these end points in a similar manner as for the pri-
mary and secondary end points:
 End points will be described as medians and IQR or
frequencies and proportions; histograms will be
generated for ordinal variables
 Binary variables will be compared using a chi-square
test and ordinal variables will be compared using a
Wilcoxon rank-sum test.
 Differences and 95% confidence intervals of
differences between study arms will be computed
 Exploratory end points will be modeled with
adjustment for baseline covariates
 Differential treatment effects will be evaluated, and
consequent subgroup effects reported
All analyses of exploratory end points will proceed
under the intent-to-treat principle. A P value of 0.05 will
be used, although emphasis will be placed on effect sizes.
We do not expect exploratory end points to be continu-
ous and normally distributed. However, any outcome
variable that meets these criteria may be compared be-
tween treatment groups using student’s t test and a lin-
ear link function will be used for modeling purposes. It
is possible that exploratory end points may be missing.
Analyses of exploratory end points in the presence of
missing outcomes will proceed using complete case ana-
lysis. A sensitivity analysis using multiple imputation for
missing outcomes will be conducted.
Summary
The analyses described here are those necessary to an-
swer the trial’s primary question of whether combined
treatment with vitamin C, thiamine and steroids is more
effective than placebo in increasing days alive and free
from respiratory and vasopressor support and reducing
mortality in patients with sepsis.
Beyond our analysis exploring the effect of treatment
on primary, secondary, and exploratory end points, we
expect there to be multiple additional exploratory ana-
lyses conducted. It is not possible to predetermine the
nature of such analyses, particularly as a rich biospeci-
men repository is being developed as a component of
this study. However, we are committed to preserving
rigor and reproducibility and will prespecify each subse-
quent analysis in the context of the specific question to
be answered, cognizant of bias and missingness in the
data.
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